Phio Pharmaceuticals Corp
Company Profile
Business description
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Contact
411 Swedeland Road
Suite 23-1080
King of PrussiaPA19406
USAT: +1 610 947-0251
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
ASX energy share remains cheap despite strong outlook
stocks
Moated AI-proof tech play hiding in the ASX 100
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,973.80 | 51.60 | -0.57% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,769.86 | 145.34 | -0.56% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,343.40 | 203.17 | 0.34% |
| NZX 50 Index | 12,886.42 | 1.49 | 0.01% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,750.60 | 48.00 | -0.55% |
| SSE Composite Index | 4,074.99 | 18.26 | -0.45% |